Mental Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
LGC
First DNA test for response to schizophrenia treatment offered in England
December 17th, 2005
LGC, an independent European analytical laboratory providing advanced chemical, biochemical and forensic analysis, has announced an exclusive agreement with King's College London to offer the first pharmacogenetic screening service that will predict whether a patient with schizophrenia will respond positively to the antipsychotic drug clozapine. The test, which will be available to the clinical community from early January 2006, is based on a panel of single nucleotide polymorphisms (SNPs) that will be analyzed using LGC's proprietary fluorescent HyBeacons DNA probe technology. Developed following 13 years of research by professor Robert Kerwin and...
Source: Mental Health Law Weekly (2005-12-17)
|
